approval

JUBBONTI (DENOSUMAB-BBDZ) — FDA approval

October 24, 2024JUBBONTIupdated 5mo ago

community read0 votes

Sponsor: SANDOZ INC. Form: INJECTABLE. Route: SUBCUTANEOUS

view source ↗

Data sources

fda approvals

last refreshed 5mo ago

Found something off?

drug timeline · 2

approvalJUBBONTI (DENOSUMAB-BBDZ) — FDA approvalOct 29, 2025 · 340d ago
approvalJUBBONTI (DENOSUMAB-BBDZ) — FDA approvalMar 5, 2024 · 943d ago

same company · ±60 days · 2

approvalUNASYN: AMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approvalSep 27, 2024
approvalGABAPENTIN: GABAPENTIN — FDA approvalDec 19, 2024

🐶 often sniffed alongside

top 4

tagApproval12 co-mentions · 3 sources
companySandoz Inc6 co-mentions · 3 sources
drugdenosumab6 co-mentions · 3 sources
drugXgeva6 co-mentions · 3 sources

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

approval

save

JUBBONTI (DENOSUMAB-BBDZ) — FDA approval

October 24, 2024JUBBONTIupdated 5mo ago

community read0 votes

Sponsor: SANDOZ INC. Form: INJECTABLE. Route: SUBCUTANEOUS

view source ↗

Data sources

fda approvals

last refreshed 5mo ago

Found something off?

drug timeline · 2

approvalJUBBONTI (DENOSUMAB-BBDZ) — FDA approvalOct 29, 2025 · 340d ago
approvalJUBBONTI (DENOSUMAB-BBDZ) — FDA approvalMar 5, 2024 · 943d ago

same company · ±60 days · 2

approvalUNASYN: AMPICILLIN AND SULBACTAM (AMPICILLIN SODIUM) — FDA approvalSep 27, 2024
approvalGABAPENTIN: GABAPENTIN — FDA approvalDec 19, 2024

🐶 often sniffed alongside

top 4

tagApproval12 co-mentions · 3 sources
companySandoz Inc6 co-mentions · 3 sources
drugdenosumab6 co-mentions · 3 sources
drugXgeva6 co-mentions · 3 sources

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

JUBBONTI (DENOSUMAB-BBDZ) — FDA approval

Report a data issue

drug timeline · 2

same company · ±60 days · 2

🐶 often sniffed alongside

comments(0)

JUBBONTI (DENOSUMAB-BBDZ) — FDA approval

Report a data issue

drug timeline · 2

same company · ±60 days · 2

🐶 often sniffed alongside

comments(0)